Literature DB >> 29476441

Association Between Body Mass Index and Disease Severity in Chinese Spinocerebellar Ataxia Type 3 Patients.

Jin-Shan Yang1,2, Ping-Ping Chen1,2, Min-Ting Lin1,2, Mei-Zhen Qian1,2,3, Hui-Xia Lin1,2, Xiao-Ping Chen4, Xian-Jin Shang5, Dan-Ni Wang1,2, Yu-Chao Chen1,2, Bin Jiang1,2,6, Yi-Jun Chen1,2, Ning Wang1,2, Wan-Jin Chen7,8, Shi-Rui Gan9,10.   

Abstract

Spinocerebellar ataxia type 3 (SCA3), the most common subtype of SCA worldwide, is caused by mutation of CAG repeats expansion in ATXN3. Body mass index (BMI) is an important modulatory factor in the progression of neurodegenerative disorders such as Huntington disease and amyotrophic lateral sclerosis. However, its relevance in SCA3 is not well understood. In this study, BMI was investigated in 134 molecularly confirmed SCA3 patients and 136 healthy controls from China. The multivariable linear regression models were performed to establish the putative risk factors for BMI, and whether BMI could affect the severity of ataxia. We found that BMI was significantly lower in the case group than that in the control group. The age at onset (positive correlation) and severity of ataxia (negative correlation) were the risk factors affecting BMI. Conversely, BMI along with the disease duration, the age at onset, and the numbers of CAG repeats could also have influence on the severity of ataxia. In conclusion, SCA3 patients had lower BMI than matched controls and BMI is a predictor of disease progression in SCA3. Nutritional intervention to promote weight gain could be a promising strategy to impede SCA3 progression.

Entities:  

Keywords:  Age at onset; Body mass index; Machado-Joseph disease; Spinocerebellar ataxia type 3

Mesh:

Year:  2018        PMID: 29476441     DOI: 10.1007/s12311-018-0929-2

Source DB:  PubMed          Journal:  Cerebellum        ISSN: 1473-4222            Impact factor:   3.847


  14 in total

Review 1.  Autosomal dominant cerebellar ataxias: polyglutamine expansions and beyond.

Authors:  Alexandra Durr
Journal:  Lancet Neurol       Date:  2010-09       Impact factor: 44.182

2.  Choosing the optimal fit function: comparison of the Akaike information criterion and the F-test.

Authors:  Gerhard Glatting; Peter Kletting; Sven N Reske; Kathrin Hohl; Christina Ring
Journal:  Med Phys       Date:  2007-11       Impact factor: 4.071

3.  Fat-free mass and its predictors in Huntington's disease.

Authors:  S D Süssmuth; V M Müller; C Geitner; G B Landwehrmeyer; S Iff; A Gemperli; Michael Orth
Journal:  J Neurol       Date:  2015-04-23       Impact factor: 4.849

4.  Percutaneous endoscopic gastrostomy and enteral nutrition in amyotrophic lateral sclerosis.

Authors:  L Mazzini; T Corrà; M Zaccala; G Mora; M Del Piano; M Galante
Journal:  J Neurol       Date:  1995-10       Impact factor: 4.849

5.  Nutritional status is a prognostic factor for survival in ALS patients.

Authors:  J C Desport; P M Preux; T C Truong; J M Vallat; D Sautereau; P Couratier
Journal:  Neurology       Date:  1999-09-22       Impact factor: 9.910

6.  CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1.

Authors:  Y Kawaguchi; T Okamoto; M Taniwaki; M Aizawa; M Inoue; S Katayama; H Kawakami; S Nakamura; M Nishimura; I Akiguchi
Journal:  Nat Genet       Date:  1994-11       Impact factor: 38.330

7.  Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial.

Authors:  Anne-Marie Wills; Jane Hubbard; Eric A Macklin; Jonathan Glass; Rup Tandan; Ericka P Simpson; Benjamin Brooks; Deborah Gelinas; Hiroshi Mitsumoto; Tahseen Mozaffar; Gregory P Hanes; Shafeeq S Ladha; Terry Heiman-Patterson; Jonathan Katz; Jau-Shin Lou; Katy Mahoney; Daniela Grasso; Robert Lawson; Hong Yu; Merit Cudkowicz
Journal:  Lancet       Date:  2014-02-28       Impact factor: 79.321

8.  Comparison of spinocerebellar ataxia type 3 mouse models identifies early gain-of-function, cell-autonomous transcriptional changes in oligodendrocytes.

Authors:  Biswarathan Ramani; Bharat Panwar; Lauren R Moore; Bo Wang; Rogerio Huang; Yuanfang Guan; Henry L Paulson
Journal:  Hum Mol Genet       Date:  2017-09-01       Impact factor: 6.150

Review 9.  Treatment for dysphagia (swallowing difficulties) in hereditary ataxia.

Authors:  Adam P Vogel; Megan J Keage; Kerstin Johansson; Ellika Schalling
Journal:  Cochrane Database Syst Rev       Date:  2015-11-13

10.  Population genetics and new insight into range of CAG repeats of spinocerebellar ataxia type 3 in the Han Chinese population.

Authors:  Shi-Rui Gan; Wang Ni; Yi Dong; Ning Wang; Zhi-Ying Wu
Journal:  PLoS One       Date:  2015-08-12       Impact factor: 3.240

View more
  4 in total

1.  Mitochondrial Dysfunction in Spinocerebellar Ataxia Type 3 Is Linked to VDAC1 Deubiquitination.

Authors:  Tina Harmuth; Jonasz J Weber; Anna J Zimmer; Anna S Sowa; Jana Schmidt; Julia C Fitzgerald; Ludger Schöls; Olaf Riess; Jeannette Hübener-Schmid
Journal:  Int J Mol Sci       Date:  2022-05-25       Impact factor: 6.208

2.  Relationship of Body Mass Index With Fuchs Endothelial Corneal Dystrophy Severity and TCF4 CTG18.1 Trinucleotide Repeat Expansion.

Authors:  Bhumi B Kinariwala; Timothy T Xu; Keith H Baratz; Ross A Aleff; Sanjay V Patel; Leo J Maguire; Michael P Fautsch; Eric D Wieben; Amy E Millen; Sangita P Patel
Journal:  Cornea       Date:  2021-12-01       Impact factor: 3.152

3.  Trehalose alleviates the phenotype of Machado-Joseph disease mouse models.

Authors:  Magda M Santana; Susana Paixão; Janete Cunha-Santos; Teresa Pereira Silva; Allyson Trevino-Garcia; Laetitia S Gaspar; Clévio Nóbrega; Rui Jorge Nobre; Cláudia Cavadas; Hagar Greif; Luís Pereira de Almeida
Journal:  J Transl Med       Date:  2020-04-09       Impact factor: 5.531

4.  Broad Influence of Mutant Ataxin-3 on the Proteome of the Adult Brain, Young Neurons, and Axons Reveals Central Molecular Processes and Biomarkers in SCA3/MJD Using Knock-In Mouse Model.

Authors:  Kalina Wiatr; Łukasz Marczak; Jean-Baptiste Pérot; Emmanuel Brouillet; Julien Flament; Maciej Figiel
Journal:  Front Mol Neurosci       Date:  2021-06-17       Impact factor: 5.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.